Skip to content
Biodatica
Start free

Radiopharm Theranostics, Ltd

Kingswood, New South Wales

OncologyPhase IListed · RADX

This company trades under its own ticker, so it sits outside Biodatica’s pre-ticker window. The record stays here because its filings are real, but the feed leaves listed companies out unless you ask for them.

Compare Sign in to watch

What changed

Phase I trial registered: HEAT Trial (HER2 Antibody Therapy With Lutetium-177)

5mo agoTrial registeredFeb 11, 2026Source filing (opens the source filing in a new tab)

Momentum

60no change

Momentum 60 out of 100, unchanged since the last recompute.

Some recent activity, at a steady rate.

Runway (estimate)

—unknown

No disclosed raise on file, so there is nothing to model from.

Stage

Phase I

The furthest-along thing in the public record. Not a projection.

Runway is an estimate: the last disclosed raise (SEC Form D) minus a modeled burn rate for the company’s stage and therapeutic area. It is not a disclosure, and companies routinely raise non-dilutive money we can’t see. How this is calculated.

Grant to raise

Every record Biodatica has resolved onto this company, newest first, each linked to the filing it came from. Where a source publishes no stable deep link for a record, the identifier is shown so you can look it up yourself.

  1. Trial

    EARLY_PHASE1 registered

    Feb 12, 2025

    HER2 Gene Mutation, Advanced Solid Tumors · RECRUITING · sponsor: Radiopharm Theranostics, Ltd · HEAT Trial (HER2 Antibody Therapy With Lutetium-177)

    ClinicalTrials.gov · NCT06824155 (opens the source filing in a new tab)

Biodatica publishes impersonal research shown identically to every subscriber. This dossier is informational only, it is not investment advice, and the momentum and runway figures are estimates derived from public filings. The underlying records are U.S. government works. Disclosures · Data sources